FINWIRES · TerminalLIVE
FINWIRES

$SPRO

2 stories mentioning SPROUpdated 20d ago

Every FINWIRES story that references SPRO, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.1% higher.HCA Healthcare (HCA) shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.NextCure (NXTC) will merge with privately held Avere Therapeutics in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.Spero Therapeutics (SPRO) has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize Innovent Biologics' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.

$HCA$IBB$NXTC$SPRO$XLV
Wire

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

GSK (GSK) and Spero Therapeutics (SPRO) said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also "generally similar" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: $52.72, Change: $+0.50, Percent Change: +0.96%

$GSK$SPRO

Track with the FINWIRES app suite

FolioX
FolioX
Track SPRO in your portfolio
WheelAI
WheelAI
Analyze SPRO options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SPRO